First line therapy in Multiple Myeloma: Overview of recent therapy in treatment of new Multiple Myeloma patients - Couverture souple

Rabea, Ahmed

 
9783846557945: First line therapy in Multiple Myeloma: Overview of recent therapy in treatment of new Multiple Myeloma patients

Synopsis

In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Présentation de l'éditeur

In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.

Biographie de l'auteur

Oncology Specialist, Assistant Lecturer of Medical Oncology, National Cancer Institite, Cairo University, Egypt. Clinical Fellow of Hemato-oncology, Princess Margaret Hospital, Toronto, Canada. Master Degree student in Advanced Oncology, Ulm University, Germany.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.